SC
KZIA

Steven Cohen’s Kazia Therapeutics KZIA Stock Holding History

Steven Cohen’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
200,300
+300
+0.2% +$3.65K ﹤0.01% 2295
2026
Q1 		$1.49M Hold
200,000
– – ﹤0.01% 2506
2025
Q4 		$1.38M Buy
+200,000
New +$1.7M ﹤0.01% 2696

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Steven Cohen's KZIA Position: Q2 2026 in Review

Steven Cohen increased its Kazia Therapeutics (KZIA) stake by 0.15% in Q2 2026, buying an estimated $3.65K and bringing the position to 200,300 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Steven Cohen first reported a position in KZIA in Q4 2025 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Steven Cohen held 200,300 shares of Kazia Therapeutics worth $2.3M as of Q2 2026.
  • Steven Cohen bought 300 Kazia Therapeutics shares in Q2 2026, an estimated $3.65K.
  • Kazia Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2295 holding.
  • Steven Cohen first reported a position in Kazia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.